

Worldwide Healthcare Trust PLC



Portfolio Manager



Samuel D. Isaly

Sven H. Borho

Information as at 31 January 2017

www.worldwidewh.com

[@WorldwideWH](https://twitter.com/WorldwideWH)

Investment Objective and Benchmark Index


To invest in the global healthcare sector with the objective of achieving a high level of capital growth. In order to achieve its investment objective, the Company invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It uses gearing, and derivative transactions to enhance returns and mitigate risk. Performance is measured against the MSCI World Health Care Index (net total return, sterling adjusted).

Cumulative Performance (%)

Trust: Worldwide Healthcare Trust PLC – NAV (ex income, total return; fully diluted)

Trust: Worldwide Healthcare Trust PLC – Share Price (total return)

Benchmark: MSCI World Health Care Index (net total return; £ adjusted)



Discrete Performance – Calendar Years (%)

Percentage Growth	2012	2013	2014	2015	2016	YTD
NAV	13.1	44.3	38.8	19.1	5.2	3.8
Share Price	20.3	47.1	39.6	13.9	10.1	0.9
Benchmark	12.2	33.6	25.6	12.7	11.2	0.4

Source: NAV (ex income total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg. Past performance is not a guide to future performance.

Commentary

In January the NAV per share was up 3.8%, the share price was up 0.9%, and the MSCI World Health Care Index was up 0.4%.

The start of 2017 was a relatively healthy one for global healthcare stocks. While the political environment in the United States remains front page news, rhetoric on putative legislation on drug pricing took a back seat in the month. Thus, all sub-sectors in healthcare advanced in January, with the exception of pharmaceuticals. Absolute performance in the month was driven by both allocation and stock selection primarily in biotechnology and medical device stocks, however, all subsectors returned positive gains. Relative (to the benchmark) performance in the month was driven by positioning in biotechnology stocks (overweight) and pharmaceutical stocks (underweight). Notable contributors were quite diverse in nature. The mid-cap biotechnology company, Incyte moved higher in the month after the company, with partner Merck, advanced their lead oncology compound, epacadostat, into registration trials. Momentum for the medical device company, Boston Scientific continued in January after the company affirmed the launch timing for their next generation transcatheter heart valve technology. The stock was higher in response. Shares in the molecular diagnostics leader, Exact Sciences rose in the period after the company announced a series of positives, including quarterly financials, increased insurance coverage for their flagship colorectal screening test, and an update on the company's product pipeline that includes a blood test for lung cancer. Finally, the last significant contributor of note in the month was once again, Actelion, a Swiss-based leader in biotechnology. After months of talks, the company finally agreed to be acquired by Johnson & Johnson for \$30 billion, representing more than an 80% premium to the unaffected share price.

The only notable detractor in the month was Bristol-Myers Squibb. The global leader in immuno-oncology announced that their accelerated filing strategy for their combination therapy in the treatment of frontline lung cancer, Opdivo + Yervoy, would not go forward as planned. While the share price was precipitously lower, our underweight positioning nevertheless led to relative gains in the month.

Biographies

Samuel D. Isaly is the Managing Partner of OrbiMed. Mr. Isaly is one of the world's foremost healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Mr. Isaly launched OrbiMed's asset management business in 1989. Mr. Isaly has a B.A. in Economics from Princeton University and a M.Sc. (Econ.) from The London School of Economics.

Sven H. Borho CFA, is a founding Partner of OrbiMed. Mr. Borho heads the public equity team and he is the portfolio manager for OrbiMed's public equity and hedge funds. Mr. Borho has played an integral role in the growth of OrbiMed's asset management activities. Mr. Borho started his career in 1991 when he joined OrbiMed's predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho was promoted to portfolio manager. Mr. Borho studied business administration at Bayreuth University in Germany and received a M.Sc. (Econ.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.

Portfolio Manager Profile

OrbiMed Capital LLC (OrbiMed) is owned by six principals, including Samuel D. Isaly, and Sven Borho who have between them many years' experience of investing in the pharmaceutical, biotechnology and healthcare sectors. The U.S. based company has over 90 investment professionals who carry out extensive research, involving company visits, developing an understanding of the commercial and scientific prospects for individual drugs. OrbiMed is registered as an investment adviser under the U.S. Securities and Exchange Commission (SEC). SEC registration does not imply a certain level of skill or training.

Investment Policy

The Company offers a superior UK-listed opportunity for capital appreciation through a diversified portfolio of worldwide pharmaceutical, biotechnology, healthcare equipment, healthcare technology and healthcare services companies. The Portfolio Manager seeks to reduce risk through extensive fundamental research, worldwide exposure, position limits, and balanced market capitalisations. The Company's investment objective also allows gearing, through borrowing, of up to 20% of net assets and a net exposure to derivative investments (excluding swaps) of up to 5% of the portfolio. Equity swaps may also be used, counterparty exposure here is limited to 12% of the portfolio at the time of acquisition.

Discount Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to the ex income NAV per share at which the shares trade to no more than 6%. Shares bought back may be held in treasury for reissue at later dates at not more than the discount at which they were purchased, and in any event at a discount no greater than 5% to the prevailing cum income net asset value per share. Any shares left in treasury are cancelled around the time of the AGM.

Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers ("IFAs") to retail private investors. The shares are excluded from the Financial Conduct Authority's ("FCA's") restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.

Worldwide Healthcare Trust PLC

10 Largest Holdings as at 31 January 2017*

Name	Region	Total
Merck & Co	North America	4.6
Boston Scientific	North America	4.5
Wright Medical Group	Europe	4.3
Alexion Pharmaceuticals	North America	4.2
Biogen	North America	3.7
Incyte	North America	3.4
HCA	North America	3.1
Ely Lilly & Co	North America	2.8
Regeneron Pharmaceuticals	North America	2.5
Allergan	North America	2.5
Total		35.6

All data in the above includes any derivative, convertible or fixed bond exposures as an economically equivalent position in the underlying asset.

Sector, Geographical* & Asset Class Breakdown at 31 January 2017**

Large Caps	70.6%	North America	65.6%	Equities	87.1%
Small Caps	29.4%	Europe	14.8%	Equity Swaps	9.3%
Total	100.0%	Emerging Markets	14.0%	Variable Bonds	1.7%
		Asia	5.6%	Fixed Bonds	1.4%
		Total	100.0%	Options	0.5%
				Total	100.0%

Source: All portfolio information sourced from Frostrow Capital LLP.

*Geographical analysis based on country of incorporation.

**Calculation based on economic exposure and expressed as a % of the total economic exposure. This includes all derivatives as an economically equivalent position in the underlying asset.

Share Price Total Return on £100 as at 31 January 2017 (£)

1 year	128.1
3 years	171.9
5 years	302.2

Source: Morningstar. Past performance is not a guide to future performance.

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Jan 12- Jan 13	Jan 13- Jan 14	Jan 14- Jan 15	Jan 15- Jan 16	Jan 16- Jan 17
NAV	21.1	38.5	41.5	-0.2	21.5
Share Price	24.5	41.3	48.1	-9.5	28.1
Benchmark	22.2	23.4	31.5	1.4	17.0

Source: NAV (ex income total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg. Past performance is not a guide to future performance.

Awards

Winner: Investment Week, Investment Company of the Year 2016, Specialist (including Hedge Funds) Category

Winner: What Investment Trust Awards 2014 Best Sector Specialist Investment Trust

Highly Commended: Money Observer Trust Awards 2014, 2015 Best Large Trust

Rated Fund: Money Observer Rated Funds 2015

Important Information

Worldwide Healthcare Trust PLC (the "Company") is a UK investment trust premium listed on the London Stock Exchange and is a member of the Association of Investment Companies. As this Company may implement a gearing policy investors should be aware that the share price movement may be more volatile than movements in the price of underlying investments. Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed. An investor may not get back the original amount invested. Changes in the rates of exchange between currencies may cause the value of investments to fluctuate. Fluctuation may be particularly marked in the case of a higher volatility fund and the value of an investment may fall suddenly and substantially. Shares in the biotechnology sector can prove volatile and above average price movements can be expected. There can be no assurance that the Company's investment objective will be achieved and investment results may vary substantially over time. This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Investment trust share prices may not fully reflect underlying net asset values. There may be a difference between the prices at which you may purchase ("the offer price") or sell ("the bid price") a share on the stock market which is known as "bid-offer" or "dealing" spread. This is set by the market makers and varies from share to share. This spread typically averages 1-2% each way on the mid-market price (the price halfway between the bid and offer prices), and can fluctuate and at times be higher than average. The net asset value per share is calculated in accordance with the guidelines of the Association of Investment Companies. Net assets are stated inclusive of income received. Any opinions on individual stocks are those of the Company's Portfolio Manager and no reliance should be given on any such views. Any research in this document has been procured and may have been acted upon by OrbiMed Capital LLC for its own purposes. The results are being made available to you only incidentally. The views expressed herein do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of Frostrow Capital LLP and no assurances are made as to their accuracy. Before investing in an investment company referred to in this advertorial, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

www.worldwidewh.com

Fast Facts as at 31 January 2017

Launch Date	April 1995
Portfolio Management Fee (payable by the Company) ^	0.65% of net assets plus 0.30% of market cap. up to £150m, 0.20% > £150m and 0.125% > £500m plus £57,500
Performance Fee ^	See Annual Report for details
Ongoing charges *	0.9%
Continuation Vote **	At the AGM every 5 years
Year / Half Year	31 March / 30 September
Capital Structure	46,506,278 Ordinary Shares

*Calculated at the financial year end, includes management fees and all other operating expenses, and excludes performance fees.

**Next vote to be held at the AGM in 2019.

^ Under new fee arrangements which will become effective on 1 April 2017, Frostrow Capital will not receive a performance fee and their annual management fee will be amended. Further details can be found in the 2016 Half Year Report. This can be found on the Company's website.

Trust Characteristics

Number of Holdings	84
Net Assets (£m)	1035.5
Market Capitalisation (£m)	992.9
Dividends	Provisional payment dates: January & July
Indicative Yield	0.8%
Gearing	6.0%
Leverage ***	Gross 117.1% Commitment 114.5%
Share Price (p)	2135.00
NAV(p) (cum income)	2226.68
(Discount) / Premium	(4.1%)

*** The Board has set the maximum leverage limit for both the Gross and the Commitment basis at 140% of the Company's Net Asset Value.

Codes

Sedol	0338530
ISIN	GB0003385308
Legal Entity Identifier	5493003YBCY4W1IMJU04
Bloomberg	WWH LN
Epic	WWH

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings, London, WC2A 1AL
Tel.: 0203 0084910
Fax: 0203 0438889
Website: www.frostrow.com

Grant Challis
Tel.: 0203 0084912
grant.challis@frostrow.com

This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the Financial Conduct Authority ("FCA").

